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Conclusion: RI AlloSCT based on BFA conditioning is feasible and
tolerable in C&A, and results in prompt achievement of durable
mixed donor chimerism and excellent OS.236
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Hurler syndrome (HS), the most severe phenotype in the spec-
trum of MPS I, is caused by a severe deficiency of the lysosomal en-
zyme alpha-L-iduronidase (IDUA). At present, hematopoietic stem
cell transplantation (HSCT) is the only treatment able to prevent
disease progression in the central nervous system and therefore con-
sidered the treatment of choice in HS patients. Since IDUA enzyme
levels after HSCT have been suggested to influence the prognosis of
HS patients, monitoring these levels after HSCT remains highly im-
portant. The current standard for biochemical monitoring after
HSCT is the leukocyte IDUA enzyme level. There is however
a high inter-laboratory variability concerning the analysis of leuko-
cyte IDUA, which makes enzyme level comparison between centers
very difficult. The use of dried blood spot (DBS) for enzyme analysis
has already been demonstrated to be an easier and less expensive
method. Furthermore, this method requires only a minimal amount
of blood and makes worldwide shipment feasible. DBS analysis
would therefore be more suitable for use in large-scale international
studies.
From 13HS patients receivingHSCT, 35 paired whole blood and
DBS samples were analyzed on leukocyte and DBS IDUA levels, re-
spectively. In order to correct for potential interfering factors, simul-
taneous assay of the alpha-Galactosidase-A (AGA) level was
performed in the DBS samples and an IDUA-AGA-ratio was calcu-
lated. A strong correlation was demonstrated between the DBS
IDUA-AGA-ratio and the leukocyte IDUA levels (r25 0,875,
p\0,001). This linear correlation was applicable to all enzyme
levels, including the levels measured early after HSCT as well as het-
erozygous levels due to mixed chimerism or the use of a carrier do-
nor. These results demonstrate that the DBS method is reliable to
monitor the biochemical effect of HSCT in HS patients. This
method is therefore a useful alternative to the conventional leukocyte
assay during the follow-up of HS patients after HSCT as well as dur-
ing large-scale international studies. In the future, the DBS method
might be extended towards monitoring the biochemical effect of
HSCT or any future therapy (eg gene therapy) on other lysosomal
storage disorders.237
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Bronchiolitis obliterans (BO) is one of the most challenging
late noninfectious complications of allogeneic hematopoietic
stem cell transplantation (HSCT). BO is associated with a pro-
gressive decline of pulmonary function secondary to air flow ob-
struction and overall survival of only 13% at 5 years. Treatment
strategies mirror that of chronic GVHD consisting of systemiccorticosteroids and augmentation or re-institution of immuno-
suppressive therapy. Response is poor with a 3-year mortality
rate of 65% when BO accompanies cGVHD. Total lymphoid ir-
radiation (TLI) has been used with some success for the treat-
ment of BO following lung transplantation but has not been
reported in the treatment of BO following allo-HSCT. We pres-
ent two pediatric patients who received TLI for refractory BO
after unrelated peripheral blood stem cell transplant (PBSCT).
The diagnosis of BO was made by an irreversible obstructive pat-
tern on pulmonary function testing, CT scans with bilateral air
trapping, and absence of infection. BO progressed despite aggres-
sive therapy with corticosteroids, tacrolimus, mycophenolate mo-
fetil, and etanercept. Patient 1 is a 15 year-old who underwent
a 9/10 (one C allele mismatch) PBSCT in 2005 for secondary
AML with TLI initiated at 30 months after PBSCT. Patient 2
is a 9 year-old who had a 10/10 PBSCT in 2006 for relapsed
ALL with TLI initiated at 26 months after PBSCT. Patients re-
ceived a total of 80 cGy of irradiation delivered in two 8 cGy
fractions per week for a total of 10 fractions. Treatment was
well tolerated with grade 1 thrombocytopenia in patient 1 and
grade 2 anemia and grade 3 thrombocytopenia in patient 2 per
CTCAE v 3.0. Patient 1 had no further decline in FEV1 with
improvement in FEV1/FVC and FEF 25%-75% at 6 months af-
ter TLI but died at 11 months post TLI due to multiple infec-
tions. Patient 2 had a dramatic increase in FEV1, FEV1/FVC,
and FEF 25%-75% that remains sustained at 10 months post
TLI. These results strongly suggest that TLI is a useful modality
in the treatment of refractory BO following allo-HSCT and
should be evaluated in future studies.
Table 1. Pulmonary Function Tests Before and After Total
Lymphoid Irradiation (TLI)
Patient #1 TLI Patient #2
at 30 months TLI at 26 monthsTime after PBSCT
FEV1 %
predictedFEV1/
FVCFEF 25% -
75% %
predicted
FEV1 %
predictedFEV1/
FVCFEF 25% -
75% %
predicted12 months 75% 92% 93% 96% 100% 118%
18 months 71% 89% 92% 93% 96% 119%
23 months 62% 80% 55% 70% 94% 102%
26 months 46% 73% 27% 54% 88% 48%
30 months 47% 67% 27% 78% 93% 101%
36 months 48% 77% 37% 95% 99% 124%Abbreviations: PBSCT (peripheral blood stem cell transplant)238
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Compared to older adults, the role of NM-HCT to cure pediatric
malignancies is not well-established and has typically been reserved
for high-risk patients (pts).We conducted a retrospective multi-cen-
ter analysis of all pts who were\22 yrs old with hematological ma-
lignancies treated on protocol to determine factors associated with
outcome after NM-HCT. Between Jan 2001-July 2008, 26 pts
with a median age of 17.9 (5.1-21.9) yrs were treated for ALL
(CR1,n5 1;CR2,n5 3;CR3,n5 5), AML (CR2,n5 5; CR4,n5 1;
PR, n5 1), Hodgkin lymphoma (CR1,n5 1; CR3, n5 2;
PR,n5 2;Ref,n5 1), MDS (n5 2), or NHL (CR3, n5 1; Rel,
n5 1). NM-HCT was chosen for concern of increased regimen-
related toxicity due to comorbidities alone (n5 11) or prior
Poster Session I S247myeloablative auto or allo-HCT with or without comorbidities
(n5 15). Median HCT-CI score was 2 (range, 0-5) (n5 25). Pts
were conditioned with either 2 Gy TBI (n5 3), or Flu 90 mg/
m2 + 2 Gy TBI (n5 23). Pts were given peripheral blood stem cells
(PBSC) (n5 24) or marrow (n5 2) grafts from HLA-identical sibs
or unrelated donors matched for 10/10 (n5 15), 9/10 (n5 5), or
8/10 (n5 1) alleles. Post-grafting immunosuppression consisted of
either CSP/MMF (n5 22), tacrolimus/MMF (n5 1), or tacroli-
mus/MMF/sirolimus (n5 3). Donor CD3 chimerism was docu-
mented in 25 pts at day 28, but was not evaluated in 1 pt who died
on day 23 after achieving normal granulocyte counts. Secondary
graft rejection occurred at day 56 in 1 pt with MDS given marrow,
who subsequently achieved full donor chimerism after a secondmye-
loablative HCTwith PBSC. Of 24 evaluable pts, 20 converted to full
donor CD3 chimerism (95-100%) while 4 remained with mixed
CD3 chimerism (15-93%). Twenty pts developed acute GVHD
(grade II5 17; III5 3) at a median of 34 (range, 9-56) days after
HCT. The cumulative incidence of chronic GVHD was 51% at 2
yrs. Causes of death included disease progression/relapse (n5 13),
complications of GVHD (n5 4), or sepsis/pulmonary complications
(n5 2). The 2 year overall survival (OS), progression-free survival,
relapse, and non-relapse mortality were 49%, 28%, 58% and 14%,
respectively. On univariate analysis, pts with HCT-CI$3 had worse
OS (p5 0.008). In this small cohort, there was no survival benefit for
pts withmyeloid vs lymphoidmalignancies or disease status at HCT.
In conclusion, NM-HCT remains an important curative option for
a subset of high-risk pediatric pts who would otherwise not qualify
for high-dose therapy, with relapse being the highest contributor
to overall mortality.239
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE
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We report the outcomes of all pediatric patients who received
high-dose chemotherapy with autologous stem cell rescue for
craniospinal (CNS) tumors at our institution. Thirty-two patients
underwent 38 autologous transplants between 2002 and 2009.
The population included 15 males and 17 females with a median
age of 66 months at diagnosis and 87 months at transplant. The
underlying diseases were medulloblastoma (56%), PNET (25%),
ATRT (13%), and pinealoblastoma (6%). Thirty-seven percent
of patients were treated for high-risk disease upfront, whereas
63% were treated for recurrent or progressive disease. The me-
dian pretransplant GFR was 119 ml/min/1.73 and 62% had hear-
ing loss. No patients had significant pre-HSCT cardiopulmonary
dysfunction. Conditioning regimens included carboplatin/thio-
tepa/etoposide (61%), carboplatin/thiotepa (21%), carboplatin/
thiotepa/VP16 (5%), thiotepa/etoposide (5%), and other (8%).
Of those that received a carboplatin-based regimen, 11% had
dose-reduction due to pre-existing organ toxicity. Median time
to engraftment was 11 days. Of the 97% of patients who survived
to discharge, the median duration of hospitalization was 20 days.
Acute complications included infection (37%), hypertension
(16%), VOD (13%), respiratory compromise (13%), renal failure
(11%), and CNS hemorrhage (8%). Four patients (11%) required
ICU care. Late complications included transverse myelitis (2 pa-
tients), varicella zoster (2 patients), and esophageal stricture (2
patients). Progressive hearing loss was reported in 9 patients.
The median duration of follow-up was 502 days. The overall sur-
vival was 72% and progression-free survival was 56%. All deaths
after discharge were due to progressive disease. Of the 12 pa-
tients who were transplanted upfront, 11 (92%) are alive without
disease progression and 1 patient died of recurrent disease (me-
dian duration of follow-up 1290 days). Of the 20 patients trans-
planted for recurrent disease, 1 died during transplant, 6 (30%)
are alive without progression, 6 (30%) are alive with progression,
and 7 (35%) are dead due to recurrent disease (median duration
of follow-up 358 days). Autologous stem cell transplant is well-tolerated with little significant toxicity in this population. Pediat-
ric patients with CNS tumors and high-risk disease who are
treated upfront appear to have better disease-free survival than
patients with recurrent disease who undergo autologous trans-
plant.240
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The Brazilian Society of Pediatric Oncology (SOBOPE) is in the
process of developing a new national protocol for the treatment of
acute lymphoblastic leukemia (ALL). Since all transplant indications
shall balance risks and benefits of each treatment modality, we would
have to know the results of hematopoietic stem cell transplants
(HSCT) performed in our country. Therefore, we analyzed the pe-
diatric data reported in a voluntary national survey of all transplants
performed for the treatment of ALL.
Methods: A questionnaire with demographic data and transplant re-
sults was sent to all Brazilian HSCT units to get data on all consec-
utive patients transplanted for ALL. The 20 years of age cut of was
chosen to allow comparison with CIBMTR data.
Results: Twenty institutions sent their data on 532 patients# 20
years. Median age was 10 years (0.5-29), 66% male. The median in-
terval from diagnosis to transplant was 2.5 years (1 mo-19 y) and me-
dian follow-up, 3 years (9 mo-14 y). Most patients were transplanted
in second remission (CR2 – 43%), followed by advanced phases
(10% CR3 and 26% in relapse) and only 19% in CR1. Matched sib-
ling donors transplant were 74% (N5 374), with a 35% 3-year over-
all survival (OS) and event free survival (EFS). HSCT results have
significantly improved over time from 27% in the early 90’s to
46% 2005-2009 (Log rank p\0.001), in a shorter follow-up. In re-
lated donor HSCT, age, conditioning therapy (+/- TBI) and graft
source did not influence survival, but EFS was 61% in CR1, 36%
in CR2 and 22% in more advanced phases (p\0.0001). Related
and unrelated donor transplants had the same results (with no adjust-
ment). Unrelated transplants were performed in 131 patients.
Age\10 years (p5 0.004), lower disease risk (p5 0.02), the use of
cord blood (p5 0.01), and TBI (p5 0.001) were associated with
a better outcome. Unrelated donor transplants had high number of
early toxic deaths and 3-yr EFS of 46% in CR1. Compared with
CIBMTR data, related donor transplants have similar results (3-yr
EFS 61% in CR1).
In conclusion, one third of our patients had HSCT for ALL in ad-
vanced stages. Results have improved in the past years for related
transplants. Disease stage was one of the most important risk factors.
After unrelated transplants, age\10 years and the use of cord blood
had better outcomes. These results will contribute to the design of
the new pediatric ALL Brazilian protocol.
